chairman and executive Director.
Taiwan Advance Bio-Pharmaceutical Inc.
"Dr. Shih has more than 15 years of experience in drug development. Her research focuses on the development of protein drug delivery, antibody discovery and targeted drug delivery with immunoliposomes. Dr. Shih joined TLC in 2002. In the role of manager/project leader, Dr. Shih is leading various research and development programs in the areas of retinal diseases and arthritis and has also accomplished the IND approvals from USFDA/TFDA. She specializes in drug development, product development strategy, non-clinical/clinical operations and planning. In addition, Dr. Shih authored in a number of scientific publications and is the inventor of novel anti-VEGF antibody and several drug delivery patents. Dr. Shih received her PhD and completed postdoctoral research from the Department of Biochemistry, College of Medicine, National Taiwan University. "